Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00910845 · ClinicalTrials.gov registry record · Phase 3
Study of Botulinum Toxin Type A for the Treatment of Patients With Idiopathic Overactive Bladder With Urinary Incontinence
A Phase 3 study of Overactive Bladder, sponsored by Allergan.
- Completed
- Registry status
- Phase 3
- Development phase
- 557
- Enrollment target
- 2
- Study locations
NCT00910845: Completed Phase 3 study of Overactive Bladder, sponsored by Allergan.
NCT00910845 is a Phase 3 study of Overactive Bladder that has completed, run by Allergan. The registered enrollment target is 557 participants, above the 195-participant average among 46 other Overactive Bladder trials with a reported enrollment target (186% higher). The trial reports 2 study locations across 2 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00910845, a Phase 3 study of Overactive Bladder, has completed, sponsored by Allergan.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 557 participants
- Enrollment target
- 2
- Study locations
Study Summary
The purpose of this study is to assess the safety and effectiveness of botulinum toxin type A (onabotulinumtoxinA) in treating patients with idiopathic overactive bladder with urinary incontinence.
Primary Outcome
A urinary incontinence episode is defined as an incident of involuntary loss of urine as recorded in a patient bladder diary during the 3 days before the Baseline and Week 12 study visits. A negative number change from baseline indicates a reduction in incontinence episodes (improvement).
Conditions Studied
Interventions
- DRUG normal saline
- BIOLOGICAL onabotulinumtoxinA
Study Locations (2)
California
- - Newport Beach
British Columbia
- - Victoria
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 557 participants |
| Start Date | 2009-09 |
| Est. Completion | 2011-07 |
| Phase | Phase 3 |
What the finished NCT00910845 record still lists
NCT00910845 is an interventional study that assigns participants to a tested intervention. The registered 557 participants enrollment target is mid-sized for trials with a published cap, above the 195-participant average among 46 other Overactive Bladder trials with a reported enrollment target (186% higher).
The record links to 1 condition, with Overactive Bladder appearing as the primary indexed condition, and to 2 interventions - of which normal saline is the first listed.
NCT00910845 reports a single indexed study location in California, British Columbia.
Frequently Asked Questions
What is clinical trial NCT00910845 about?
NCT00910845 is a clinical study titled "Study of Botulinum Toxin Type A for the Treatment of Patients With Idiopathic Overactive Bladder With Urinary Incontinence". The purpose of this study is to assess the safety and effectiveness of botulinum toxin type A (onabotulinumtoxinA) in treating patients with idiopathic overactive bladder with urinary incontinence.
What is the current status of trial NCT00910845?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 557 participants. The study started on 2009-09. Estimated completion is 2011-07.
What conditions does trial NCT00910845 study?
This clinical trial studies the following conditions: Overactive Bladder.
What interventions are being tested in trial NCT00910845?
The interventions under investigation include: normal saline (DRUG), onabotulinumtoxinA (BIOLOGICAL).
Who is sponsoring clinical trial NCT00910845?
This trial is sponsored by Allergan, which has 314 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00910845 being conducted?
This trial has 2 study locations across California, British Columbia. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Overactive Bladder
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT00910845's enrollment target sits among peer trials
557 3rd of 46 higher than 44 of 46 other Overactive Bladder trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Overactive Bladder trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Anticholinergic vs. Botox Comparison Study
COMPLETED · Phase 3
-
Behavioral or Solifenacin Therapy for Urinary Symptoms in Parkinson Disease
COMPLETED · Phase 3
-
Home Versus Office Removal of Percutaneous Nerve Evaluation (PNE) Lead
RECRUITING · NA
-
Bladder Botox UTI Antibiotic Prophylaxis
RECRUITING · Phase 4
-
Percutaneous Nerve Evaluation Trial Time
RECRUITING · NA
-
Noninvasive Ultrasound Assessment of Detrusor Dysfunction
RECRUITING
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT05708885 · 557 participants · NA
Striated Esophageal Motor Function Modulation in Health and Disease
- NCT07173751 · 558 participants · Phase 3
ROSETTA Breast-01: The Effects and Safety of Pumitamig in Patients With Triple-Negative Breast Cancer
- NCT06074588 · 556 participants · Phase 3
Sacituzumab Tirumotecan (MK-2870) Versus Chemotherapy in Previously Treated Advanced or Metastatic Nonsquamous Non-small Cell Lung Cancer (NSCLC) With EGFR Mutations or Other Genomic Alterations (MK-2870-004)
- NCT06693622 · 556 participants
Patient Preferences for Barrett's Esophagus and Esophageal Cancer Screening Tests
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia